First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
Sanjay Popat, MD, PhD, The Royal Marsden Hospital, London, United Kingdom, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer (NSCLC).
Results demonstrated strong and durable antitumor activity with consistent benefit across HER2 mutation subtypes and a manageable safety profile. These results support zongertinib as a promising targeted option for patients with HER2-mutated NSCLC and reinforce the growing role of precision therapies in lung cancer care.
These results were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
Source:
Popat S, Yamamoto N, Girard N, et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: BEAMION-LUNG 1. Presented at the 2025 ESMO Congress. October 17-21, 2025; Berlin, Germany. LBA74
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
